Kalaris Therapeutics Inc (KLRS) FinancialsKLRSKalaris Therapeutics Inc

Evaluating the bottom line, Kalaris Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -79.91%, provide a clear picture of how effectively KLRS converts its operational activities into shareholder value.

In the context of the broader market, KLRS competes directly with industry leaders such as CRBU and ELTX. With a market capitalization of $57.60M, it holds a leading position in the sector. When comparing efficiency, KLRS's gross margin of N/A stands against CRBU's 100.00% and ELTX's N/A. Such benchmarking helps identify whether Kalaris Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Kalaris Therapeutics has reported consistent net losses, with a net income to common of -$18,268,000 in Q4 2024 and -$10,856,000 in Q1 2026. The current ratio is strong at 12.19, indicating good short-term financial health despite losses.